{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:53:08Z","timestamp":1793764388872,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the widespread use of the blockade of immune checkpoints, for a significant number of cancer patients, these therapies have proven ineffective, presumably due to the immunosuppressive nature of the tumor microenvironment (TME). Critical drivers of immune escape in the TME include tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which not only mediate immune suppression, but also facilitate metastatic dissemination and impart resistance to immunotherapies. Thus, strategies that convert them into tumor fighters may offer great therapeutic potential. In this study, we evaluated whether pharmacologic modulation of macrophage phenotype by HDAC inhibitors (HDACi) could produce an anti-tumor effect. We demonstrated that low-dose HDACi trichostatin-A (TSA) markedly reshaped the tumor immune microenvironment by modulating the suppressive activity of infiltrating macrophages and inhibiting the recruitment of MDSCs in various tumors. These actions, in turn, augmented anti-tumor immune responses and further enhanced anti-tumor effects of immunotherapies. HDAC inhibition, however, also upregulated PD-L1, thereby limiting the beneficial therapeutic effects. Indeed, combining low-dose TSA with anti-PD-L1 in this model significantly enhanced the durability of tumor reduction and prolonged survival of tumor-bearing mice, compared with the effect of either treatment alone. These data introduce HDAC inhibition as a potential means to harness the anti-tumor potential of macrophages in cancer therapy.<\/jats:p>","DOI":"10.1038\/s41388-020-01636-x","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T16:58:23Z","timestamp":1612889903000},"page":"1836-1850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2697-6496","authenticated-orcid":false,"given":"Xiaolei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsha","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-9342","authenticated-orcid":false,"given":"Changshun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9716-2126","authenticated-orcid":false,"given":"Yufang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"1636_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41423-018-0086-z","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol. 2019;16:28\u201339.","journal-title":"Cell Mol Immunol"},{"key":"1636_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31.","journal-title":"J Hematol Oncol"},{"key":"1636_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","volume":"574","author":"O Demaria","year":"2019","unstructured":"Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45\u201356.","journal-title":"Nature"},{"key":"1636_CR4","doi-asserted-by":"publisher","first-page":"a003285.","DOI":"10.1101\/cshperspect.a003285","volume":"3","author":"LM Coussens","year":"2011","unstructured":"Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011;3:a003285.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1636_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nri2528","volume":"9","author":"JW Pollard","year":"2009","unstructured":"Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9:259\u201370.","journal-title":"Nat Rev Immunol"},{"key":"1636_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-306","volume":"12","author":"C Medrek","year":"2012","unstructured":"Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306.","journal-title":"BMC Cancer"},{"key":"1636_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","volume":"108","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914\u201323.","journal-title":"Br J Cancer"},{"key":"1636_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1102-3","volume":"18","author":"X Li","year":"2019","unstructured":"Li X, Liu R, Su X, Pan Y, Han X, Shao C, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer. 2019;18:177.","journal-title":"Mol Cancer"},{"key":"1636_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"1636_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"1636_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4049\/jimmunol.171.3.1232","volume":"171","author":"PC Rodriguez","year":"2003","unstructured":"Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003;171:1232\u20139.","journal-title":"J Immunol"},{"key":"1636_CR12","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","volume":"75","author":"N Gul","year":"2015","unstructured":"Gul N, van Egmond M. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: a Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer Res. 2015;75:5008\u201313.","journal-title":"Cancer Res"},{"key":"1636_CR13","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA. 2015;112:6140\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1636_CR14","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695\u2013710.","journal-title":"J Exp Med"},{"key":"1636_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1172\/JCI66776","volume":"124","author":"N Gul","year":"2014","unstructured":"Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, et al. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Investig. 2014;124:812\u201323.","journal-title":"J Clin Investig"},{"key":"1636_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"N Azad","year":"2013","unstructured":"Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 2013;10:256\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"1636_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91\u2013107.","journal-title":"Nat Rev Clin Oncol"},{"key":"1636_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2020;17:75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1636_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tcb.2018.07.006","volume":"29","author":"H Loo Yau","year":"2019","unstructured":"Loo Yau H, Ettayebi I, De, Carvalho DD. The Cancer Epigenome: exploiting Its Vulnerabilities for Immunotherapy. Trends Cell Biol. 2019;29:31\u201343.","journal-title":"Trends Cell Biol"},{"key":"1636_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri.2017.146","volume":"18","author":"AN Henning","year":"2018","unstructured":"Henning AN, Roychoudhuri R, Restifo NP. Epigenetic control of CD8(+) T cell differentiation. Nat Rev Immunol. 2018;18:340\u201356.","journal-title":"Nat Rev Immunol"},{"key":"1636_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452\u20136.","journal-title":"Nature"},{"key":"1636_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell. 2017;170:142\u201357 e119.","journal-title":"Cell"},{"key":"1636_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ni.3325","volume":"17","author":"I Amit","year":"2016","unstructured":"Amit I, Winter DR, Jung S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat Immunol. 2016;17:18\u201325.","journal-title":"Nat Immunol"},{"key":"1636_CR24","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","volume":"345","author":"S Saeed","year":"2014","unstructured":"Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345:1251086.","journal-title":"Science"},{"key":"1636_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"1636_CR26","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/onc.2015.46","volume":"34","author":"K Cao","year":"2015","unstructured":"Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y, et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015;34:5960\u201370.","journal-title":"Oncogene"},{"key":"1636_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S, et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017;23:5187\u2013201.","journal-title":"Clin Cancer Res"},{"key":"1636_CR28","doi-asserted-by":"publisher","first-page":"1734268","DOI":"10.1080\/2162402X.2020.1734268","volume":"9","author":"Z Xie","year":"2020","unstructured":"Xie Z, Ikegami T, Ago Y, Okada N, Tachibana M. Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression. Oncoimmunology. 2020;9:1734268.","journal-title":"Oncoimmunology"},{"key":"1636_CR29","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.1252510","volume":"344","author":"RA Franklin","year":"2014","unstructured":"Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921\u20135.","journal-title":"Science"},{"key":"1636_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02899217","volume":"54","author":"N van Rooijen","year":"1988","unstructured":"van Rooijen N, Kors N, ter Hart H, Claassen E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54:241\u20135.","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"1636_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Investig. 2018;128:580\u20138.","journal-title":"J Clin Investig"},{"key":"1636_CR32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI96113","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Investig. 2018;128:805\u201315.","journal-title":"J Clin Investig"},{"key":"1636_CR33","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y, et al. Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Res. 2019;79:1493\u2013506.","journal-title":"Cancer Res"},{"key":"1636_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14\u201320.","journal-title":"Immunity"},{"key":"1636_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589\u2013602.","journal-title":"Cancer Cell"},{"key":"1636_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.celrep.2018.06.040","volume":"24","author":"A Nguyen","year":"2018","unstructured":"Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, et al. HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. Cell Rep. 2018;24:642\u201354.","journal-title":"Cell Rep."},{"key":"1636_CR37","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","volume":"125","author":"S Ugel","year":"2015","unstructured":"Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Investig. 2015;125:3365\u201376.","journal-title":"J Clin Investig"},{"key":"1636_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","volume":"31","author":"SJ Van Dyken","year":"2013","unstructured":"Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317\u201343.","journal-title":"Annu Rev Immunol"},{"key":"1636_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2009-01-200931","volume":"114","author":"F Pucci","year":"2009","unstructured":"Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood \u201cresident\u201d monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 2009;114:901\u201314.","journal-title":"Blood"},{"key":"1636_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017;543:428\u201332.","journal-title":"Nature"},{"key":"1636_CR41","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","volume":"125","author":"D Marvel","year":"2015","unstructured":"Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Investig. 2015;125:3356\u201364.","journal-title":"J Clin Investig"},{"key":"1636_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci USA. 2020;117:1129\u201338.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1636_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579:284\u201390.","journal-title":"Nature"},{"key":"1636_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"1636_CR45","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. J Cancer. 2020;11:4059\u201372.","journal-title":"J Cancer"},{"key":"1636_CR46","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1189\/jlb.0509363","volume":"87","author":"MA Halili","year":"2010","unstructured":"Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol. 2010;87:1103\u201314.","journal-title":"J Leukoc Biol"},{"key":"1636_CR47","doi-asserted-by":"publisher","first-page":"105973","DOI":"10.1016\/j.intimp.2019.105973","volume":"77","author":"SN Cui","year":"2019","unstructured":"Cui SN, Chen ZY, Yang XB, Chen L, Yang YY, Pan SW, et al. Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis. Int Immunopharmacol. 2019;77:105973.","journal-title":"Int Immunopharmacol"},{"key":"1636_CR48","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264\u201372.","journal-title":"Nat Med"},{"key":"1636_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18:557\u201364.","journal-title":"Neuro Oncol"},{"key":"1636_CR50","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","volume":"67","author":"TM Nywening","year":"2018","unstructured":"Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, et al. Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67:1112\u201323.","journal-title":"Gut"},{"key":"1636_CR51","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.4049\/jimmunol.178.10.6616","volume":"178","author":"E Cittera","year":"2007","unstructured":"Cittera E, Leidi M, Buracchi C, Pasqualini F, Sozzani S, Vecchi A, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol. 2007;178:6616\u201323.","journal-title":"J Immunol"},{"key":"1636_CR52","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1073\/pnas.1011037108","volume":"108","author":"AJ Christiansen","year":"2011","unstructured":"Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci USA. 2011;108:4141\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1636_CR53","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","volume":"65","author":"S Armeanu","year":"2005","unstructured":"Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321\u20139.","journal-title":"Cancer Res"},{"key":"1636_CR54","doi-asserted-by":"publisher","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","volume":"65","author":"S Skov","year":"2005","unstructured":"Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136\u201345.","journal-title":"Cancer Res"},{"key":"1636_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000195","volume":"8","author":"J Laengle","year":"2020","unstructured":"Laengle J, Kabiljo J, Hunter L, Homola J, Prodinger S, Egger G, et al. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis. J Immunother Cancer. 2020;8:e000195.","journal-title":"J Immunother Cancer"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01636-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-01636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:19:38Z","timestamp":1684603178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01636-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,3,10]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01636-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The mice were housed in cages with a constant-flow air exchange supporting specific pathogen-free conditions. Animal care was in full compliance with the guide for the care and use of laboratory animals and the Institutional Animal Care and Use Committee of the Soochow University approved all protocols. There is no human subject participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}